CA2468619A1 - Fragments et conjugues de l'adiponectine - Google Patents
Fragments et conjugues de l'adiponectine Download PDFInfo
- Publication number
- CA2468619A1 CA2468619A1 CA002468619A CA2468619A CA2468619A1 CA 2468619 A1 CA2468619 A1 CA 2468619A1 CA 002468619 A CA002468619 A CA 002468619A CA 2468619 A CA2468619 A CA 2468619A CA 2468619 A1 CA2468619 A1 CA 2468619A1
- Authority
- CA
- Canada
- Prior art keywords
- adiponectin polypeptide
- seq
- adiponectin
- polypeptide
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Abstract
L'invention concerne un conjugué comprenant un polypeptide de l'adiponectine, et une première fraction non polypeptidique liée de manière covalente au polypeptide de l'adiponectine. Le polypeptide de l'adiponectine comprend un résidu d'amino-acide ayant un groupe de fixation pour la première fraction non polypeptidique. Ledit résidu d'amino-acide a été introduit dans une position qui, dans l'adiponectine parent, est occupée par un résidu d'amino-acide exposé en surface.
Applications Claiming Priority (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34348201P | 2001-12-21 | 2001-12-21 | |
DKPA200101952 | 2001-12-21 | ||
US60/343,482 | 2001-12-21 | ||
DKPA200101952 | 2001-12-21 | ||
US37549202P | 2002-04-25 | 2002-04-25 | |
DKPA200200627 | 2002-04-25 | ||
US60/375,492 | 2002-04-25 | ||
DKPA200200627 | 2002-04-25 | ||
US39411702P | 2002-07-03 | 2002-07-03 | |
DKPA200201036 | 2002-07-03 | ||
DKPA200201036 | 2002-07-03 | ||
US60/394,117 | 2002-07-03 | ||
US41216902P | 2002-09-20 | 2002-09-20 | |
DKPA200201385 | 2002-09-20 | ||
DKPA200201385 | 2002-09-20 | ||
US60/412,169 | 2002-09-20 | ||
PCT/DK2002/000897 WO2003055916A2 (fr) | 2001-12-21 | 2002-12-20 | Fragments et conjugues de l'adiponectine |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2468619A1 true CA2468619A1 (fr) | 2003-07-10 |
Family
ID=27570813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002468619A Abandoned CA2468619A1 (fr) | 2001-12-21 | 2002-12-20 | Fragments et conjugues de l'adiponectine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1458758A2 (fr) |
JP (1) | JP2005526492A (fr) |
AU (1) | AU2002358467A1 (fr) |
CA (1) | CA2468619A1 (fr) |
WO (1) | WO2003055916A2 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ534699A (en) | 2002-01-18 | 2008-12-24 | Protemix Corp Ltd | Glycoisoforms of adiponectin and uses thereof |
EP1506229A1 (fr) * | 2002-05-17 | 2005-02-16 | Serono Genetics Institute S.A. | Fragments d'obg3 inhibant la conversion d'obg3 actif en obg3 de plus faible activite et autres compositions pour le traitement de troubles metaboliques |
DE60333917D1 (de) * | 2002-05-31 | 2010-10-07 | Serono Genetics Inst Sa | Homotrimerer, erweiterter globulärer kopf von obg3 und verwendungen davon |
US7176292B2 (en) * | 2003-09-11 | 2007-02-13 | Dialean, Ltd. | Ghrelin variant protein |
US20080139468A1 (en) * | 2004-03-31 | 2008-06-12 | Kazuhisa Maeda | Method For Control of Invasion and Use of Adiponectin |
WO2006061853A2 (fr) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Nouveaux composes erythropoietiques et leur procede de production |
US7592423B2 (en) | 2005-01-07 | 2009-09-22 | Xencor, Inc. | Globular adiponectin variants |
US7749956B2 (en) | 2005-01-07 | 2010-07-06 | Xencor, Inc. | Method of treatment using adiponectin variants |
AU2006203832A1 (en) * | 2005-01-07 | 2006-07-13 | Xencor | Adiponectin variants |
WO2006104964A2 (fr) * | 2005-03-28 | 2006-10-05 | University Of Louisville Research Foundation, Inc. | Inhibition de la forme humide de la degenerescence maculaire liee a l'age (age related macular degeneration / amd), par de l'adiponectine ou acrp 30 |
CN1740195B (zh) * | 2005-04-15 | 2012-01-04 | 复旦大学 | 一种多肽gapM1及其制备方法 |
US7709607B2 (en) | 2005-07-11 | 2010-05-04 | Xencor, Inc. | Adiponectin variants |
WO2007008937A2 (fr) * | 2005-07-11 | 2007-01-18 | Xencor | Variants d'adiponectine |
JP2009502849A (ja) * | 2005-07-29 | 2009-01-29 | ラボラトワール セローノ ソシエテ アノニム | 血栓症及び癌の治療、及び/又は予防のためのacrp30の使用 |
EP1981526A4 (fr) * | 2006-01-09 | 2011-03-02 | Childrens Hosp Medical Center | L'adiponectine pour le traitement de divers troubles |
WO2008067599A1 (fr) * | 2006-12-04 | 2008-06-12 | Apollo Life Sciences Limited | Molécules isolées de leptine et d'adiponectine et molécules chimériques de celles-ci |
US8026345B2 (en) * | 2007-01-08 | 2011-09-27 | Hoffmann-La Roche Inc. | Characterization and identification of unique human adiponectin isoforms and antibodies |
CN103228290A (zh) | 2011-02-18 | 2013-07-31 | (株)斯坦帝尔 | 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物 |
CN104004066B (zh) * | 2013-02-26 | 2017-05-31 | 上海市第一人民医院 | 预防或抑制炎症反应和血管新生的小分子多肽及其应用 |
WO2018004067A1 (fr) * | 2016-07-01 | 2018-01-04 | 전남대학교 산학협력단 | Lignée cellulaire de surexpression d'adiponectine |
CN112209995B (zh) * | 2020-10-14 | 2022-01-11 | 华兰基因工程有限公司 | 一种SARS-CoV-2表面蛋白受体结合区制备方法 |
CN112521481B (zh) * | 2020-12-08 | 2022-11-04 | 武汉市工程科学技术研究院 | 表面修饰物及其制备方法和应用 |
CN112574306B (zh) * | 2020-12-17 | 2023-05-05 | 武汉华美生物工程有限公司 | 脂联素单克隆抗体、抗体对及其制备方法和用途 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL74177A (en) * | 1984-02-03 | 1989-09-10 | Abbott Lab | Stabilized enzyme conjugate composition containing a calcium salt and a polyethylene glycol |
PT1248849E (pt) * | 2000-01-14 | 2008-09-08 | Serono Genetics Inst Sa | Cabeça globular obg3 e suas utilizações para reduzir a massa corporal |
-
2002
- 2002-12-20 EP EP02792711A patent/EP1458758A2/fr not_active Withdrawn
- 2002-12-20 AU AU2002358467A patent/AU2002358467A1/en not_active Abandoned
- 2002-12-20 WO PCT/DK2002/000897 patent/WO2003055916A2/fr not_active Application Discontinuation
- 2002-12-20 CA CA002468619A patent/CA2468619A1/fr not_active Abandoned
- 2002-12-20 JP JP2003556446A patent/JP2005526492A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2003055916A2 (fr) | 2003-07-10 |
WO2003055916A3 (fr) | 2003-12-31 |
AU2002358467A1 (en) | 2003-07-15 |
EP1458758A2 (fr) | 2004-09-22 |
JP2005526492A (ja) | 2005-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2468619A1 (fr) | Fragments et conjugues de l'adiponectine | |
US7232562B2 (en) | E38N interferon gamma polypeptide variants | |
US7419805B2 (en) | Polynucleotides encoding S99T interferon gamma polypeptide variants and means of expression | |
EP1366075A2 (fr) | Nouvelles molecules de type interferon beta | |
CZ20022727A3 (cs) | Polypeptidový konjugát, způsob jeho výroby a farmaceutický prostředek | |
JP2005506317A (ja) | G−cfs結合体 | |
US20030186386A1 (en) | Interleukin 10 | |
US20060052292A1 (en) | Adiponectin fragments and conjugates | |
US7390638B2 (en) | S99T C-11 Truncated polynucleotides encoding interferon gamma polypeptide variants | |
JP2004524020A (ja) | 改良された成長ホルモン分子 | |
WO2001058950A1 (fr) | Interleukine-10 amelioree | |
EP1328295A2 (fr) | Nouvelles molecules analogues a l'interferon beta | |
US7230081B1 (en) | Interferon gamma conjugates | |
NZ528651A (en) | Glycosylated interferon gamma polypeptide variants | |
US7524931B2 (en) | Full-length interferon gamma polypeptide variants | |
AU2002252971B2 (en) | Interferon gamma polypeptide variants | |
AU782635B2 (en) | Interferon gamma conjugates | |
ZA200308376B (en) | Interferon gamma polypeptide variants. | |
AU2002252971A1 (en) | Interferon gamma polypeptide variants | |
AU2002235727A1 (en) | New interferon beta-like molecules | |
CZ20033016A3 (cs) | Varianty polpeptidu interferonu gamma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |